Cases & Deals

  • Home
  • Practices
  • AbbVie partners to develop a novel trispecific antibody candidate in multiple myeloma

Share

AbbVie partners to develop a novel trispecific antibody candidate in multiple myeloma

January 2025

Client(s) AbbVie Inc.

Jones Day advised AbbVie Inc. on a strategic collaboration and option-to-license agreement with Simcere Zaiming to develop a novel trispecific antibody candidate in multiple myeloma. 

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.